Giant Cell Tumor of Mandible : A Case Report
We present a rare case of giant cell tumor of mandible. Patient was a 33 years old lady who presented with gradually progressive painful swelling in chin. After exclusion of distant metastasis by F-18 FDG PET scan, she underwent en-bloc resection of the tumor with free fibula flap reconstruction. During 6 months of follow up visit patient had no recurrence. (Source: Indian Journal of Otolaryngology and Head and Neck Surgery)
Source: Indian Journal of Otolaryngology and Head and Neck Surgery - December 19, 2023 Category: ENT & OMF Source Type: research
Denosumab and Mortality in a Real ‐World Setting: A Comparative Study
This study examined the association between Dmab and all-cause mortality compared with no treatment in subjects with a fracture and BPs in subjects without a fracture. The study population was from the Sax Institute's 45 and Up Study (n = 267,357), a prospective population-based cohort with questionnaire data linked to hospital admissions (Admitted Patients Data Collection [APDC] data were linked by the Centre for Health Record Linkage), medication records (Pharmaceutical Benefits Scheme [PBS] provided by Services Australia), and stored securely (secure data access was provided through the Sax Institute's Secure Unifie...
Source: Journal of Bone and Mineral Research - December 16, 2023 Category: Orthopaedics Authors: Dunia Alarkawi,
Thach Tran,
Weiwen Chen,
Lyn M March,
Fiona M Blyth,
Robert D Blank,
Dana Bliuc,
Jacqueline R Center Tags: Research Article Source Type: research
Establishment of bone-targeted nano-platform and the study of its combination with 2-deoxy-d-glucose enhanced photodynamic therapy to inhibit bone metastasis
In this study, zoledronic acid (ZOL) demonstrated excellent bone-targeting properties as a bone-targeting ligand. The metal-organic framework (MOF) known as ZIF-90 was modified with ZOL to construct a bone-targeting-based drug delivery system. Chlorin e6 (Ce6) was loaded in the bone-targeted drug delivery system and combined with 2-deoxy-D-glucose (2-DG), which successfully treated bone tumors when enhanced photodynamic therapy was applied. The Ce6@ZIF-PEG-ZOL (Ce6@ZPZ) nanoparticles were observed to have uniform morphology, a particle size of approximately 210 nm, and a potential of approximately -30.4 mV. The results of ...
Source: Journal of the Mechanical Behavior of Biomedical Materials - December 13, 2023 Category: Materials Science Authors: Wanzhen Li Yongqi Yang Jun Wang Ting Ge Shuixia Wan Lin Gui Yugui Tao Ping Song Liangjun Yang Fei Ge Weiwei Zhang Source Type: research
Establishment of bone-targeted nano-platform and the study of its combination with 2-deoxy-d-glucose enhanced photodynamic therapy to inhibit bone metastasis
In this study, zoledronic acid (ZOL) demonstrated excellent bone-targeting properties as a bone-targeting ligand. The metal-organic framework (MOF) known as ZIF-90 was modified with ZOL to construct a bone-targeting-based drug delivery system. Chlorin e6 (Ce6) was loaded in the bone-targeted drug delivery system and combined with 2-deoxy-D-glucose (2-DG), which successfully treated bone tumors when enhanced photodynamic therapy was applied. The Ce6@ZIF-PEG-ZOL (Ce6@ZPZ) nanoparticles were observed to have uniform morphology, a particle size of approximately 210 nm, and a potential of approximately -30.4 mV. The results of ...
Source: Journal of the Mechanical Behavior of Biomedical Materials - December 13, 2023 Category: Materials Science Authors: Wanzhen Li Yongqi Yang Jun Wang Ting Ge Shuixia Wan Lin Gui Yugui Tao Ping Song Liangjun Yang Fei Ge Weiwei Zhang Source Type: research
Zoledronic-acid
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research
Medication-related osteonecrosis of the jaw: A cross-sectional study on the prevalence of cutaneous manifestations and the primary care physician's role in its early diagnosis
Bone-modifying agents (BMA), such as nitrogen-containing bisphosphonates (N-BP) s)(e.g., zoledronic acid, pamidronate, alendronate and risedronate) and receptor activators of nuclear factor kappa- Β ligand inhibitors (e.g., denosumab), are commonly used for treating osteoporosis, bone metastases, and other bone-related diseases. Side effects of Stevens–Johnson syndrome and toxic epidermal necrolysis in patients using N-BPshave been reported.1 In addition, maculopapular lesions,2 plaques an d ulcerations,3 dermatitides, and B-cell pseudolymphoma4 were reported in patients taking zoledronic acid. (Source: The American Journal of Medicine)
Source: The American Journal of Medicine - November 30, 2023 Category: General Medicine Authors: Sara Whitefield, Mor Bar Ilan, Towy Sorel Lazarovici, Silvina Friedlander-Barenboim, Riad Kassem, Yarom Noam Tags: Clinical Research Study Source Type: research
The use of advanced-platelet rich fibrin (A-PRF) in the management of medication-related osteonecrosis of the jaw (MRONJ): A case report
Clin Case Rep. 2023 Nov 25;11(11):e8259. doi: 10.1002/ccr3.8259. eCollection 2023 Nov.ABSTRACTMedication-related osteonecrosis of the jaws (MRONJ) is a serious debilitating disease resulting from long-term treatment with Antiresorptive drugs such as Bisphosphonates or Denosumab, which significantly affects patients' quality of life. A 43-year-old female patient with stage 4 breast cancer and treated with Zoledronic Acid for bone metastases was referred to the Department of Oral Medicine at the Faculty of Dentistry, Damascus University. The main complaint was pain in the right maxilla. Intraoral examination showed an exposu...
Source: Clinical Breast Cancer - November 29, 2023 Category: Cancer & Oncology Authors: Maan Ahmad Rafik Asfour Abeer Ahmad Aljoujou Maher Sadik Saifo Haya A L Jabban Source Type: research
The use of advanced-platelet rich fibrin (A-PRF) in the management of medication-related osteonecrosis of the jaw (MRONJ): A case report
Clin Case Rep. 2023 Nov 25;11(11):e8259. doi: 10.1002/ccr3.8259. eCollection 2023 Nov.ABSTRACTMedication-related osteonecrosis of the jaws (MRONJ) is a serious debilitating disease resulting from long-term treatment with Antiresorptive drugs such as Bisphosphonates or Denosumab, which significantly affects patients' quality of life. A 43-year-old female patient with stage 4 breast cancer and treated with Zoledronic Acid for bone metastases was referred to the Department of Oral Medicine at the Faculty of Dentistry, Damascus University. The main complaint was pain in the right maxilla. Intraoral examination showed an exposu...
Source: Clinical Genitourinary Cancer - November 29, 2023 Category: Cancer & Oncology Authors: Maan Ahmad Rafik Asfour Abeer Ahmad Aljoujou Maher Sadik Saifo Haya A L Jabban Source Type: research
Zoledronic acid sequential to teriparatide may promote greater inhibition of bone resorption than zoledronic acid alone
CONCLUSION: ZOL-administered sequential to TPTD yielded deeper and more prolonged bone resorption suppression than ZOL alone. Prospective data are needed to confirm whether in a sequential treatment scenario, subsequent ZOL dosing interval should be less frequent.PMID:38028331 | PMC:PMC10666713 | DOI:10.1177/20420188231213639 (Source: Adv Data)
Source: Adv Data - November 29, 2023 Category: Epidemiology Authors: Sharon Giveon Galia Zacay Iris Vered A Joseph Foldes Liana Tripto-Shkolnik Source Type: research
The use of advanced-platelet rich fibrin (A-PRF) in the management of medication-related osteonecrosis of the jaw (MRONJ): A case report
Clin Case Rep. 2023 Nov 25;11(11):e8259. doi: 10.1002/ccr3.8259. eCollection 2023 Nov.ABSTRACTMedication-related osteonecrosis of the jaws (MRONJ) is a serious debilitating disease resulting from long-term treatment with Antiresorptive drugs such as Bisphosphonates or Denosumab, which significantly affects patients' quality of life. A 43-year-old female patient with stage 4 breast cancer and treated with Zoledronic Acid for bone metastases was referred to the Department of Oral Medicine at the Faculty of Dentistry, Damascus University. The main complaint was pain in the right maxilla. Intraoral examination showed an exposu...
Source: Clinical Breast Cancer - November 29, 2023 Category: Cancer & Oncology Authors: Maan Ahmad Rafik Asfour Abeer Ahmad Aljoujou Maher Sadik Saifo Haya A L Jabban Source Type: research
The use of advanced-platelet rich fibrin (A-PRF) in the management of medication-related osteonecrosis of the jaw (MRONJ): A case report
Clin Case Rep. 2023 Nov 25;11(11):e8259. doi: 10.1002/ccr3.8259. eCollection 2023 Nov.ABSTRACTMedication-related osteonecrosis of the jaws (MRONJ) is a serious debilitating disease resulting from long-term treatment with Antiresorptive drugs such as Bisphosphonates or Denosumab, which significantly affects patients' quality of life. A 43-year-old female patient with stage 4 breast cancer and treated with Zoledronic Acid for bone metastases was referred to the Department of Oral Medicine at the Faculty of Dentistry, Damascus University. The main complaint was pain in the right maxilla. Intraoral examination showed an exposu...
Source: Clinical Genitourinary Cancer - November 29, 2023 Category: Cancer & Oncology Authors: Maan Ahmad Rafik Asfour Abeer Ahmad Aljoujou Maher Sadik Saifo Haya A L Jabban Source Type: research
The use of advanced ‐platelet rich fibrin (A‐PRF) in the management of medication‐related osteonecrosis of the jaw (MRONJ): A case report
Intraoral examination, exposed necrotic bone with purulent exudate. AbstractMedication-related osteonecrosis of the jaws (MRONJ) is a serious debilitating disease resulting from long-term treatment with Antiresorptive drugs such as Bisphosphonates or Denosumab, which significantly affects patients' quality of life. A 43-year-old female patient with stage 4 breast cancer and treated with Zoledronic Acid for bone metastases was referred to the Department of Oral Medicine at the Faculty of Dentistry, Damascus University. The main complaint was pain in the right maxilla. Intraoral examination showed an exposure of necrotic bon...
Source: Clinical Case Reports - November 26, 2023 Category: General Medicine Authors: Maan Ahmad Rafik Asfour,
Abeer Ahmad Aljoujou,
Maher Sadik Saifo,
Haya A. L. Jabban Tags: CASE REPORT Source Type: research
Protocol of a randomised trial of teriparatide followed by zoledronic acid to reduce fracture risk in adults with osteogenesis imperfecta
Introduction
Osteogenesis imperfecta (OI) is a rare genetic disease associated with multiple fractures throughout life. It is often treated with osteoporosis medications but their effectiveness at preventing fractures is unknown. The Treatment of Osteogenesis Imperfecta with Parathyroid Hormone and Zoledronic Acid trial will determine if therapy with teriparatide (TPTD) followed by zoledronic acid (ZA) can reduce the risk of clinical fractures in OI.
Methods and analysis
Individuals aged ≥18 years with a clinical diagnosis of OI are eligible to take part. At baseline, participants will undergo a spine X-ray, and have b...
Source: BMJ Open - November 22, 2023 Category: General Medicine Authors: Hald, J. D., Keerie, C., Weir, C. J., Javaid, M. K., Lam, W., Osborne, P., Walsh, J., Langdahl, B. L., Ralston, S. H. Tags: Open access, Rheumatology Source Type: research
Treatment Effect of Zoledronic Acid in Chronic Non-bacterial Osteomyelitis of the Jaw: A Case Series
AbstractChronic non-bacterial osteomyelitis (CNO) is an autoinflammatory, osteolytic bone disorder sometimes localized to a unifocal site in the jaw, causing long-term pain and reduced function. The aim of this study was to describe the patients with CNO of the jaw, focusing on treatment with zoledronic acid for pain relief. An analysis of medical records of 24 patients with CNO of the jaw, including treatment with zoledronic acid and effects on pain relief. Descriptive statistics and nonparametric tests were used to describe the population and compare treatment effects, respectively. The average treatment period was 33.4 ...
Source: Calcified Tissue International - November 22, 2023 Category: Orthopaedics Source Type: research
